Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been recommended as the first-line therapy for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, acquired resistance to EGFR-TKIs is inevitable. Although immune checkpoint blockades (ICBs) tar...
Main Authors: | Di Wu, Yangyang Liu, Xiaoting Li, Yiying Liu, Qifan Yang, Yuting Liu, Jingjing Wu, Chen Tian, Yulan Zeng, Zhikun Zhao, Yajie Xiao, Feifei Gu, Kai Zhang, Yue Hu, Li Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.01366/full |
Similar Items
-
Progress in Neoantigen Targeted Cancer Immunotherapies
by: Xue-Jiao Han, et al.
Published: (2020-07-01) -
pTuneos: prioritizing tumor neoantigens from next-generation sequencing data
by: Chi Zhou, et al.
Published: (2019-10-01) -
Mutation-Derived Neoantigens for Cancer Immunotherapy
by: John C. Castle, et al.
Published: (2019-08-01) -
The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma
by: Hirokazu Matsushita, et al.
Published: (2017-08-01) -
Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy
by: Yicheng Zhu, et al.
Published: (2021-06-01)